News & Updates

Frontline nelitolimod plus pembrolizumab combo elicits response in advanced melanoma

The toll-like receptor 9 agonist nelitolimod, when combined with pembrolizumab, shows promising antitumour activity in treatment-naïve patients with anti–PD-1/PD-L1 advanced melanoma, according to a phase II open-label trial.

Electroacupuncture reduces early urinary incontinence burden after RP

Electroacupuncture helps reverse urinary incontinence following radical prostatectomy (RP) for prostate cancer, according to a study from China.

Model predicts cardiomyopathy risk in childhood cancer survivors

Researchers have recently developed prediction models with highest-to-date performance to estimate the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer.

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

Childhood ALL burden drops but inequalities persist

The global burden of childhood acute lymphoblastic leukemia (ALL) has gradually decreased, with steady improvements in quality of care, but inequalities remain a significant challenge, according to a study.

Painful, blistering, severe sunburns tied to cutaneous squamous cell carcinoma

Individuals exposed to increased frequencies of painful, blistering, and/or severe sunburns throughout their lifetime have increased odds of cutaneous squamous cell carcinoma (cSCC), according to a systematic review and meta-analysis.

Cancer treatment personalization with biomarkers: What lies ahead?

Pembrolizumab plus chemo efficacious in advanced PSCC

Treatment with the combination of pembrolizumab plus chemotherapy elicits response in patients with advanced penile squamous cell carcinoma (PSCC) while having a manageable safety profile, according to the phase II HERCULES trial.